Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMJX3O8)

Drug Name
OSI-027 Drug Info
Cross-matching ID
PubChem CID
135398516
ChEBI ID
CHEMBL91363
CAS Number
CAS 936890-98-1
TTD Drug ID
D0H7XL

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
ECM-receptor interaction 2.33 0.00e+0 80/88 (90.91%) ITGA6;ITGB5;LAMC2;...
Focal adhesion 1.95 4.12e-3 180/201 (89.55%) ITGA6;MET;IGF1R;...
Small cell lung cancer 1.93 2.75e-3 90/92 (97.83%) MYC;ITGA6;CDKN1B;...
Proteoglycans in cancer 1.92 2.06e-3 172/205 (83.9%) MYC;MET;IGF1R;...
Arrhythmogenic right ventricular cardiomyopathy 1.76 3.13e-2 70/77 (90.91%) ITGA6;ITGB5;DSG2;...
Wnt signaling pathway 1.75 2.75e-2 124/166 (74.7%) MYC;SMAD3;SFRP1;...
FoxO signaling pathway 1.74 2.71e-2 118/131 (90.08%) SMAD3;IGF1R;TNFSF10;...
Adherens junction 1.74 2.47e-2 63/71 (88.73%) SMAD3;MET;IGF1R;...
Transcriptional misregulation in cancer 1.73 2.38e-2 158/192 (82.29%) MYC;DUSP6;MET;...
Apelin signaling pathway 1.66 4.37e-2 117/137 (85.4%) CCN2;SMAD3;PLAT;...
MicroRNAs in cancer 1.64 4.64e-2 146/310 (47.1%) MYC;MET;PLAU;...
Bladder cancer 1.63 4.87e-2 40/41 (97.56%) MYC;THBS1;RPS6KA5;...
TGF-beta signaling pathway 1.63 4.75e-2 81/94 (86.17%) MYC;SMAD3;INHBA;...
Caffeine metabolism -1.59 4.83e-2 5/6 (83.33%) CYP2A6;NAT2;NAT1
Huntington disease -1.60 4.34e-2 233/306 (76.14%) NDUFB1;PSMC1;PSMC5;...
Synaptic vesicle cycle -1.62 3.99e-2 63/78 (80.77%) NAPA;ATP6V1B2;ATP6V0D1;...
Pentose phosphate pathway -1.62 4.00e-2 25/30 (83.33%) TKT;PFKM;FBP1;...
PPAR signaling pathway -1.67 2.56e-2 66/74 (89.19%) ACOX1;PCK1;HMGCS2;...
Fructose and mannose metabolism -1.67 2.52e-2 30/33 (90.91%) PFKFB2;PFKM;FBP1;...
Glutathione metabolism -1.69 2.18e-2 43/57 (75.44%) GPX3;LAP3;GCLC;...
Bile secretion -1.72 1.81e-2 68/90 (75.56%) SLCO1B3;ABCC4;BAAT;...
Antigen processing and presentation -1.72 1.73e-2 60/78 (76.92%) CD4;RFX5;PSME2;...
Legionellosis -1.72 1.81e-2 51/57 (89.47%) HSPD1;TLR5;MYD88;...
Collecting duct acid secretion -1.74 1.42e-2 22/27 (81.48%) ATP6V0C;ATP6V1B2;ATP6V0D1;...
Citrate cycle (TCA cycle) -1.74 1.50e-2 30/30 (100%) CS;PDHA1;SDHC;...
Amyotrophic lateral sclerosis -1.77 9.23e-3 267/364 (73.35%) NUP160;NDUFB1;PSMC1;...
Oxidative phosphorylation -1.80 6.98e-3 93/133 (69.92%) NDUFB1;COX10;NDUFB2;...
Biosynthesis of unsaturated fatty acids -1.81 6.68e-3 21/27 (77.78%) HACD3;ACOX3;HACD1;...
Parkinson disease -1.82 6.33e-3 176/249 (70.68%) PARK7;PSMA2;MFN1;...
Steroid hormone biosynthesis -1.85 4.24e-3 43/61 (70.49%) HSD3B2;DHRS11;SRD5A1;...
Ferroptosis -1.86 4.57e-3 36/41 (87.8%) CYBB;GCLC;ATG5;...
Glycine, serine and threonine metabolism -1.86 3.96e-3 31/40 (77.5%) AOC2;BHMT;SRR;...
Tryptophan metabolism -1.87 3.24e-3 35/42 (83.33%) CAT;ALDH3A2;CYP1B1;...
Prion disease -1.88 3.56e-3 209/273 (76.56%) NDUFB1;PSMC1;PSMC5;...
Cysteine and methionine metabolism -1.89 3.96e-3 43/50 (86%) GCLC;GOT2;CTH;...
Glycolysis / Gluconeogenesis -1.91 1.48e-3 56/67 (83.58%) LDHC;HK1;HK3;...
Protein export -1.97 1.70e-3 17/23 (73.91%) SEC61A2;SRPRA;SEC63;...
Arginine and proline metabolism -2.06 0.00e+0 39/50 (78%) PRODH;LAP3;GOT2;...
Terpenoid backbone biosynthesis -2.07 0.00e+0 18/22 (81.82%) HMGCS2;DHDDS;FDPS;...
Proteasome -2.17 0.00e+0 44/46 (95.65%) PSMB5;PSMA2;PSMC1;...
Protein processing in endoplasmic reticulum -2.23 0.00e+0 127/171 (74.27%) ERO1B;TRAM1;SEC23A;...
Steroid biosynthesis -2.30 0.00e+0 19/20 (95%) CYP27B1;LSS;HSD17B7;...
Folate biosynthesis -2.31 0.00e+0 23/26 (88.46%) GGH;MOCOS;MOCS2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
SK-BR-3 CVCL_0033 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Breast carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-20 CVCL_0178 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Hs 578T CVCL_0332 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Normal (Epithelial)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HME1 CVCL_2950 Homo sapiens 0.04uM - 10uM 3H, 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 2.22uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
LNCaP CVCL_0395 Homo sapiens 0.04uM - 10uM 3H, 24H
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H